Subscribe
Core coverageAMLX

Company profile / AMLX

Amylyx Pharmaceuticals

Clinaptis stanceConstructive
ConvictionMedium
Ticker
AMLX
Exchange
NASDAQ
Coverage
Standard profile
Updated
Sep 11, 2026
Metabolic / Endocrinology

Clinical-stage biopharmaceutical company developing therapies across endocrine and neurodegenerative diseases. Its lead asset, avexitide, is a first-in-class GLP-1 receptor antagonist moving toward a U.S. filing after positive Phase 3 LUCIDITY data in post-bariatric hypoglycemia.

01 / Clinaptis view

The current read

Constructive. LUCIDITY delivered a 55% placebo-adjusted reduction in Level 2 and Level 3 hypoglycemic events, almost exactly inside Clinaptis's pre-readout 49–58% modeled range, while meeting all secondary endpoints with favorable tolerability.

  1. The pivotal efficacy risk is resolved. At $32.09 per share and an approximately $3.57 billion market capitalization on September 11, following the pricing of a $500.2 million gross equity raise, much of the approval-event upside identified in our July note has been realized.
  2. The remaining thesis is regulatory and commercial: whether the first potential PBH therapy can expand diagnosis and referral beyond today's recognized patient pool. RELYVRIO's 2022 ALS approval and 2024 voluntary market withdrawal after the confirmatory PHOENIX failure are now in the rear-view mirror rather than the driver of the current equity story.
02 / Consensus gap

Where the market may differ

PBH is a niche market, but the addressable market is not the same as the currently diagnosed one. Clinaptis's pre-readout work argued that approval, an expanded-access pathway and disease education could convert part of a much larger diagnosable population into treated patients.

  1. With clinical success now demonstrated and the valuation materially higher than the approximately $1.72 billion enterprise value used in that work, upside depends less on approval probability and more on filing quality, label breadth, pricing, reimbursement and the pace at which Amylyx can build the diagnosis funnel.
Coverage state
Standard profile
What the review turns on
Key variable

Whether regulatory execution and commercial disease-building convert a positive Phase 3 result into meaningful penetration of the diagnosable PBH population

Next catalyst

Avexitide · Detailed LUCIDITY presentation at an upcoming medical meeting; NDA submission for post-bariatric hypoglycemia · By year-end 2026

03 / Pipeline

Key programs

4 assets · 5 programs

AssetIndicationStageNext event
Avexitide
Post-bariatric hypoglycemia
Phase 3 completed / NDA preparation
Detailed LUCIDITY presentation at an upcoming medical meeting and NDA submission planned by year-end 2026; potential launch in 2027 if approved
Congenital hyperinsulinism
Clinical development planning
Physician and community engagement to define next clinical-development steps
AMX0035
Wolfram syndrome
Phase 2 completed / Phase 3 planning
FDA alignment on a focused pivotal Phase 3 study
AMX0114
Amyotrophic lateral sclerosis
Phase 1
Continued LUMINA dose escalation and biomarker updates; Cohort 3 was enrolling as of the 2Q26 update
AMX0318
Post-bariatric hypoglycemia and other rare diseases
IND-enabling
IND filing targeted for 2027
04 / Connected research

Published on AMLX

View full archive
  1. 01

    AMLX: Ph3 PBH Readout Less Binary Than It Looks

    Three independent statistical frameworks suggest 3Q26 LUCIDITY readout is materially more derisked than prevailing investor confidence implies.

    Read